Epilepsy is prevalent with about 50 million patients affected worldwide. There are many treatment gaps in the management of epilepsy in India. Within Anti-epileptic drugs (AED), Brivaracetam, which is a high-affinity, selective, and reversible ligand for synaptic vesicle 2A is approved by the Food and Drug Administration for monotherapy as well as adjunctive treatment of focal seizures. A series of meeting occurring during April 2020 inviting neurologist across India as panel members, reviewed the efficacy and safety of brivaracetam and discussed the use of brivaracetam in clinical settings and the drivers and barriers for the use of brivaracetam in the management of epilepsy. Brivaracetam has good efficacy and tolerability as adjunctive therapy in the treatment of focal (partial onset) seizures in patients 16 years of age and older. Brivaracetam is safe for prolonged use in patients with epilepsy and in children with epilepsy. The most common adverse events with brivaracetam are related to central nervous system and include fatigue, dizziness, and somnolence; these may improve or resolve during treatment. A consensus was sought for the use of brivaracetam in epilepsy management in routine neurology practices Brivaracetam is a safer AED with lesser behavioral AEs, lack of cognitive impairment, and no clinically relevant drug-drug interactions or dose adjustment for renal patients.
| Published in | European Journal of Clinical and Biomedical Sciences (Volume 7, Issue 6) |
| DOI | 10.11648/j.ejcbs.20210706.11 |
| Page(s) | 86-93 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
Brivaracetam, Epilepsy, Fecal-onset Seizures, Adjunctive Therapy, Antiepileptic Drugs
| [1] | Santhosh NS, Sinha S, Satishchandra P. Epilepsy: Indian perspective. Ann Indian Acad Neurol. 2014; 17: S3-S11. |
| [2] | Meyer AC, Dua T, Ma J, Shekhar S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ. 2010 Apr; 88: 260-6. |
| [3] | Haroon A, Tripathi M, Khanam R, Vohora D. Antiepileptic drugs prescription utilization behavior and direct costs of treatment in a national hospital of India. Ann Indian Acad Neurol. 2012; 15: 289-293. |
| [4] | Duncan JS. The promise of new antiepileptic drugs. Br J Clin Pharmacol. 2002; 53: 123-131. |
| [5] | Hanaya R, Arita K. The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications. Neurol Med Chir (Tokyo). 2016; 56: 205-220. |
| [6] | Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand Suppl. 2005; 181: 30-35. |
| [7] | Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011; 664: 36−44. |
| [8] | US Food and Drug Administration. Brivaracetam [prescribing information]. 2016. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-briviact-treat-partial-onset-seizures. Accessed June 15, 2020. |
| [9] | Rigo JM, Nguyen L, Hans G. UCB 34714: effect on inhibitory and excitatory neurotransmission. Epilepsia. 2004; 45: 56. |
| [10] | Niespodziany I, Lukyanetz EA, Matagne A, Matagne A, Klitgaard H, Wolff C. Brivaracetam does not modulate the major ionic conductances in neurons. Epilepsia. 2015; 56192–193. |
| [11] | Kostyuk PG, Lukyanetz EA, Klitgaard H, Margineanu D-G. UCB 34714, a new pyrrolidone derivative, without impact on high- and low-voltage activated calcium currents in rat isolated neurons. Epilepsia. 2004; 45: 141. |
| [12] | Otoul C, Watanabe S, McCabe S, Stockis A. Relative bioavailability and bioequivalence of brivaracetam 10 mg/mL oral solution and 50-mg film-coated tablet. Clin Pharmacol Drug Dev. 2017; 6: 313–317. |
| [13] | Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007; 63: 680–688. |
| [14] | Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008; 66: 71-75. |
| [15] | Sargentini-Maier ML, Espié P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008; 36: 36–45. |
| [16] | Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol. 2013; 53: 633–64. |
| [17] | Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the tenth Eilat Conference (EILATX). Epilepsy Res. 2010; 92: 89–124. |
| [18] | Nicolas JM, Hannestad J, Holden D, Kervyn S Nabulsi N, Tytgat D et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016; 57: 201–209. |
| [19] | Feyissa AM. Brivaracetam in the treatment of epilepsy: a review of clinical trial data. Neuropsychiatr Dis Treat. 2019; 15: 2587-2600. |
| [20] | Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia. 2014; 55: e27–e31. |
| [21] | Stockis A, Watanabe S, Scheen AJ, Tytgat D, Gerin D, Rosa M, et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Dispos. 2016; 44: 792–799. |
| [22] | Doganavsargil-Baysal O, Cinemre B, Senol Y, Barcin E, Gokmen Z. Epilepsy and stigmatization in Turkey. J Epilepsy Behavior. 2017; 73: 100-5. |
| [23] | Robertson J, Hatton C, Emerson E, Baines S. Prevalence of epilepsy among people with intellectual disabilities: A systematic review. Seizure. 2015; 29: 46-62. |
| [24] | Jaiswal S, Kumar S, Sharma CS, Kuchhal A, Jaiswal A. Psychiatric Comorbidities in Patients with Epilepsy: A Cross-sectional Study. Int J Adv Integ Med Sci 2017; 2: 24-28. |
| [25] | Michaelis R, Tang V, Wagner JL, Modi AC, LaFrance WC Goldstein LH, et al. Psychological treatments for people with epilepsy. Cochrane Database Syst Rev. 2017; 10: CD012081. |
| [26] | Gur-Ozmen S, Leibetseder A, Cock HR, Agrawal N, von Oertzen TJ. Screening of anxiety and quality of life in people with epilepsy. Seizure. 2017; 45: 107-113. |
| [27] | Zhu LN, Chen D, Chen T, Xu D, Chen SH, Liu L. The adverse event profile of brivaracetam: A meta-analysis of randomized controlled trials. Seizure. 2017; 45: 7-16. |
| [28] | Zhang L, Li S, Li H, Zou X. Levetiracetam vs. brivaracetam for adults with refractory focal seizures: A meta-analysis and indirect comparison. Seizure. 2016; 39: 28-33. |
| [29] | Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018; 10: 1-22. |
| [30] | O’Brien TJ, Borghs S, He Q, Schulz AL, Yates S, Biton V. Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial. Epilepsia 2020; 61: 636-646. |
| [31] | Lee SK. Epilepsy in the Elderly: Treatment and Consideration of Comorbid Diseases. J Epilepsy Res. 2019; 9: 27-35. |
| [32] | Brodie MJ, Whitesides J, Schiemann J, D'Souza J, Johnson ME. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. Epilepsy Res. 2016; 127: 114-118. |
| [33] | Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016 Jul; 57: 1139-51. |
| [34] | Coppola G, Iapadre G, Operto FF, Verrotti A. New developments in the management of partial-onset epilepsy: role of brivaracetam. Drug Des Devel Ther. 2017; 11: 643-657. |
| [35] | Strzelczyk A, Steinig I, Willems LM, Reif PS, Senft C, Voss M, et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals. Epilepsy Behav. 2017; 70: 177-181. |
| [36] | Klein P, Johnson ME, Schiemann J, Whitesides J. Time to onset of sustained ≥50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment. Epilepsia. 2017; 58: e21–e25. |
| [37] | Villanueva V, López-González FJ, Mauri JA, Uranga JR, Gadea MO, Montoya J et al. BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand. 2019; 139: 360-368. |
| [38] | Schoemaker R, Wade JR, D'Souza J, Stockis A. Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures. Epilepsy Res. 2017; 137: 95-100. |
| [39] | Witt JA, Elger CE, Helmstaedter C. Short-term and longer-term effects of brivaracetam on cognition and behavior in a naturalistic clinical setting-Preliminary data. Seizure. 2018; 62: 49-54. |
| [40] | Liu E, Dilley D, McDonough B, Stockis A, Daniels T. Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial. Paediatr Drugs. 2019; 21: 291-301. |
| [41] | Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D’Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from Levetiracetam to Brivaracetam. Epilepsy Behav 2015; 52: 165–8. |
| [42] | Brodie MJ, Fakhoury T, McDonough B, Colson AO, Stockis A, Elmoufti S, et al. Brivaracetam-induced elevation of carbamazepine epoxide levels: a post-hoc analysis from the clinical development program. Epilepsy Res. 2018; 145: 55–62. |
| [43] | Stockis A, Chanteux H, Rosa M, Rolan P. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015; 113: 19–27. |
| [44] | Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000 Oct; 97: 464-8. |
| [45] | Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014; 55: 57-66. |
| [46] | Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014; 55: 47-56. |
| [47] | Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013; 54: 89-97. |
| [48] | Steinhoff BJ, Bacher M, Bucurenciu I, Hillenbrand B, Intravooth T, Kornmeier R. et al. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey. Seizure. 2017; 48: 11-14. |
| [49] | Ma J, Huang S, You C. Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials. Epilepsy Res. 2015; 114: 59-65. |
| [50] | Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: A systematic review and meta-analysis. Neurology. 2016 Apr 5; 86: 1344-1352. |
APA Style
A. V. Srinivasan, Kumar Gaurav, Arundhati Ghosh, Sukhpreet Singh. (2021). Expert Opinion: Brivaracetam in Management of Epilepsy. European Journal of Clinical and Biomedical Sciences, 7(6), 86-93. https://doi.org/10.11648/j.ejcbs.20210706.11
ACS Style
A. V. Srinivasan; Kumar Gaurav; Arundhati Ghosh; Sukhpreet Singh. Expert Opinion: Brivaracetam in Management of Epilepsy. Eur. J. Clin. Biomed. Sci. 2021, 7(6), 86-93. doi: 10.11648/j.ejcbs.20210706.11
AMA Style
A. V. Srinivasan, Kumar Gaurav, Arundhati Ghosh, Sukhpreet Singh. Expert Opinion: Brivaracetam in Management of Epilepsy. Eur J Clin Biomed Sci. 2021;7(6):86-93. doi: 10.11648/j.ejcbs.20210706.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ejcbs.20210706.11,
author = {A. V. Srinivasan and Kumar Gaurav and Arundhati Ghosh and Sukhpreet Singh},
title = {Expert Opinion: Brivaracetam in Management of Epilepsy},
journal = {European Journal of Clinical and Biomedical Sciences},
volume = {7},
number = {6},
pages = {86-93},
doi = {10.11648/j.ejcbs.20210706.11},
url = {https://doi.org/10.11648/j.ejcbs.20210706.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejcbs.20210706.11},
abstract = {Epilepsy is prevalent with about 50 million patients affected worldwide. There are many treatment gaps in the management of epilepsy in India. Within Anti-epileptic drugs (AED), Brivaracetam, which is a high-affinity, selective, and reversible ligand for synaptic vesicle 2A is approved by the Food and Drug Administration for monotherapy as well as adjunctive treatment of focal seizures. A series of meeting occurring during April 2020 inviting neurologist across India as panel members, reviewed the efficacy and safety of brivaracetam and discussed the use of brivaracetam in clinical settings and the drivers and barriers for the use of brivaracetam in the management of epilepsy. Brivaracetam has good efficacy and tolerability as adjunctive therapy in the treatment of focal (partial onset) seizures in patients 16 years of age and older. Brivaracetam is safe for prolonged use in patients with epilepsy and in children with epilepsy. The most common adverse events with brivaracetam are related to central nervous system and include fatigue, dizziness, and somnolence; these may improve or resolve during treatment. A consensus was sought for the use of brivaracetam in epilepsy management in routine neurology practices Brivaracetam is a safer AED with lesser behavioral AEs, lack of cognitive impairment, and no clinically relevant drug-drug interactions or dose adjustment for renal patients.},
year = {2021}
}
TY - JOUR T1 - Expert Opinion: Brivaracetam in Management of Epilepsy AU - A. V. Srinivasan AU - Kumar Gaurav AU - Arundhati Ghosh AU - Sukhpreet Singh Y1 - 2021/11/19 PY - 2021 N1 - https://doi.org/10.11648/j.ejcbs.20210706.11 DO - 10.11648/j.ejcbs.20210706.11 T2 - European Journal of Clinical and Biomedical Sciences JF - European Journal of Clinical and Biomedical Sciences JO - European Journal of Clinical and Biomedical Sciences SP - 86 EP - 93 PB - Science Publishing Group SN - 2575-5005 UR - https://doi.org/10.11648/j.ejcbs.20210706.11 AB - Epilepsy is prevalent with about 50 million patients affected worldwide. There are many treatment gaps in the management of epilepsy in India. Within Anti-epileptic drugs (AED), Brivaracetam, which is a high-affinity, selective, and reversible ligand for synaptic vesicle 2A is approved by the Food and Drug Administration for monotherapy as well as adjunctive treatment of focal seizures. A series of meeting occurring during April 2020 inviting neurologist across India as panel members, reviewed the efficacy and safety of brivaracetam and discussed the use of brivaracetam in clinical settings and the drivers and barriers for the use of brivaracetam in the management of epilepsy. Brivaracetam has good efficacy and tolerability as adjunctive therapy in the treatment of focal (partial onset) seizures in patients 16 years of age and older. Brivaracetam is safe for prolonged use in patients with epilepsy and in children with epilepsy. The most common adverse events with brivaracetam are related to central nervous system and include fatigue, dizziness, and somnolence; these may improve or resolve during treatment. A consensus was sought for the use of brivaracetam in epilepsy management in routine neurology practices Brivaracetam is a safer AED with lesser behavioral AEs, lack of cognitive impairment, and no clinically relevant drug-drug interactions or dose adjustment for renal patients. VL - 7 IS - 6 ER -
Information
Email: